Key Takeaways GSK lifted its sales and earnings projections for the year, after a strong performance by its HIV and cancer drugs drove second-quarter sales higher. The British pharmaceutical firm said sales rose 13% year-over-year to 7.88 billion pounds ($10.12 billion), beating analysts' estimates. GSK said it expects sales growth between 7% and 9% this year, up from its prior forecast, but cut its vaccine sales outlook. GSK (GSK) lifted its sales and earnings projections for the year, after a strong perfo ...